About: Relacorilant

Property	Value
dbo:abstract	Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is also under development for the treatment of solid tumors and alcoholism. The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown. (en)
dbo:casNumber	1496510-51-0
dbo:class	dbr:Antiglucocorticoid
dbo:fdaUniiCode	2158753C7E
dbo:kegg	D11336
dbo:pubchem	73051463
dbo:thumbnail	wiki-commons:Special:FilePath/Relacorilant.svg?width=300
dbo:wikiPageExternalLink	http://adisinsight.springer.com/drugs/800041622
dbo:wikiPageID	56104974 (xsd:integer)
dbo:wikiPageLength	3454 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1084240921 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Antiglucocorticoid dbr:Cushing's_syndrome dbc:Experimental_drugs dbc:Fluoroarenes dbc:Ketones dbc:Trifluoromethyl_compounds dbr:Chemical_compound dbr:Oral_administration dbc:Antiglucocorticoids dbr:Clinical_trial dbr:Receptor_antagonist dbr:Tumor dbr:Alcoholism dbc:Pyrazoles dbr:Nonsteroidal dbr:Glucocorticoid_receptor dbc:Pyridines dbc:Isoquinolines dbc:Sulfonamides dbr:Phases_of_clinical_research
dbp:c	27 (xsd:integer)
dbp:casNumber	1496510 (xsd:integer)
dbp:chemspiderid	57617720 (xsd:integer)
dbp:class	dbr:Antiglucocorticoid
dbp:f	4 (xsd:integer)
dbp:h	22 (xsd:integer)
dbp:iupacName	[-1--6-sulfonyl-4,5,7,8-tetrahydropyrazolo[3,4-g]isoquinolin-4a-yl]-[4-pyridin-2-yl]methanone (en)
dbp:kegg	D11336 (en)
dbp:n	6 (xsd:integer)
dbp:o	3 (xsd:integer)
dbp:pubchem	73051463 (xsd:integer)
dbp:routesOfAdministration	dbr:Oral_administration
dbp:s	1 (xsd:integer)
dbp:smiles	CN1C=CSN2CCC3=CC4=CC=NN4C6=CC=CF (en)
dbp:stdinchi	1 (xsd:integer)
dbp:stdinchikey	WANIDIGFXJFFEL-SANMLTNESA-N (en)
dbp:synonyms	CORT-125134 (en)
dbp:unii	2158753 (xsd:integer)
dbp:wikiPageUsesTemplate	dbt:Drugbox dbt:Glucocorticoid_receptor_modulators dbt:Reflist dbt:Short_description dbt:Systemic-hormonal-drug-stub
dcterms:subject	dbc:Experimental_drugs dbc:Fluoroarenes dbc:Ketones dbc:Trifluoromethyl_compounds dbc:Antiglucocorticoids dbc:Pyrazoles dbc:Pyridines dbc:Isoquinolines dbc:Sulfonamides
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug
rdfs:comment	Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is also under development for the treatment of solid tumors and alcoholism. The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown. (en)
rdfs:label	Relacorilant (en)
owl:sameAs	wikidata:Relacorilant https://global.dbpedia.org/id/4XLxg
prov:wasDerivedFrom	wikipedia-en:Relacorilant?oldid=1084240921&ns=0
foaf:depiction	wiki-commons:Special:FilePath/Relacorilant.svg
foaf:isPrimaryTopicOf	wikipedia-en:Relacorilant
is dbo:wikiPageRedirects of	dbr:CORT-125,134 dbr:CORT-125134 dbr:CORT125134 dbr:CORT_125,134 dbr:CORT_125134
is dbo:wikiPageWikiLink of	dbr:Corcept_Therapeutics dbr:CORT-125,134 dbr:CORT-125134 dbr:CORT125134 dbr:CORT_125,134 dbr:CORT_125134
is foaf:primaryTopic of	wikipedia-en:Relacorilant